View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Felix Fischer
  • Felix Fischer

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: AMS Osram

Felix Fischer ... (+5)
  • Felix Fischer
  • Filipe Botelho
  • Haidje Rustau
  • Jayanth Kandalam
  • Si Yong Ng

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: House of HR, AMS Osram, Intrum, Vallourec, Nemak, Ardagh, Voyage Care, Solenis, Oriflame

Valneva SE: 1 director

A director at Valneva SE bought 20,000 shares at 2.540EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

 PRESS RELEASE

Valneva annonce la levée de la restriction temporaire de l'Agence euro...

Valneva annonce la levée de la restriction temporaire de l'Agence européenne des médicaments sur l'utilisation du vaccin contre le chikungunya IXCHIQ® chez les personnes âgées Saint Herblain (France), le 11 juillet 2025 – (Nasdaq: VALN; Euronext Paris: VLA), (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence européenne des médicaments (EMA) allait lever sa restriction temporaire sur la vaccination des personnes âgées de 65 et plus avec le vaccin à dose unique contre le chikungunya IXCHIQ® de Valneva suite à l’achèvement d’une ...

 PRESS RELEASE

Valneva Announces Lifting of European Medicines Agency’s Temporary Res...

Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly Saint Herblain (France), July, 11 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva’s single-dose chikungunya vaccine IXCHIQ® by EMA’s safety committee (PRAC). The committee initiated its review at the beginning of May following the occurrence of serious sid...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch